KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade
Status:
Recruiting
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
The study is an interventional phase II clinical trial aiming to evaluate the efficacy and
safety of KN046, a PD-L1 and CTLA-4 bispecific antibody, in combination with regorafenib or
apatinib for microsatellite instability-high digestive system cancers resistant to PD-1/PD-L1
blockade. KN046 plus regorafenib will be given for patients with colorectal cancers, and
KN046 plus apatinib will be given for patients with gastric cancers (including
esophageal-gastric junction cancers) and other kinds of digestive system cancers.